June 2019

OBGYN

CHANGES TO ENDOMENTRIAL CANCER TREATMENT WITH DANIELA MATEI, MD

Featuring: Daniela Matei, MD

Episode Summary

Results from a randomized phase 3 clinical trial, published in The New England Journal of Medicine, could change the way women are treated for later stage endometrial cancer. Northwestern’s Daniela Matei, MD, explains.

Endometrial cancer is the most common of gynecologic cancers: More than 62,000 cases are diagnosed per year. A woman's lifetime risk for developing endometrial cancer is about 3 percent. At the same time, mortality from endometrial cancer has also been going up by about 1.6 percent a year in the United States.

Patients are typically treated with chemotherapy, and those with stage 3/4A, at higher risk of reoccurrence, are also given radiation. A new study led by Daniela Matei, MD, (GOG-258 trial) published in The New England Journal of Medicine, found that radiation plus chemotherapy doesn’t improve endometrial cancer recurrence-free survival and that chemotherapy alone should be the standard treatment for these women.

Continuing Medical Education Credit

Physicians who listen to this podcast may claim continuing medical education credit after listening to an episode of this program.

This podcast was originally release via the Feinberg School of Medicine News Center in June 2019. 
Daniela Matei, MD
  • Diana, Princess of Wales Professor of Cancer Research
  • Professor of Medicine in the Division of Hematology and Oncology
  • Professor of Obstetrics and Gynecology in the Division of Gynecologic Oncology
  • Co-leader of the Translational Research in Solid Tumors Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University
  • Gynecologic Oncologist, Northwestern Medicine

Refer a Patient

Northwestern Medicine welcomes the opportunity to partner with you in caring for your patients. ​

You May Also Like